A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia
This study is ongoing, but not recruiting participants.
Sponsor:
Kasiak Research Pvt. Ltd.
Information provided by (Responsible Party):
Kasiak Research Pvt. Ltd.
ClinicalTrials.gov Identifier:
NCT01643629
First received: July 12, 2012
Last updated: July 24, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a multicentre, open label, randomized, pilot study to evaluate safety and efficacy of Human Platelet Lysate (HPL) in subjects with Androgenetic Alopecia. The study is being conducted at 2 centers in India. The primary endpoints are Improvement in Caliber & Density of hair and Improvement in Photographic assessment from randomization to end of study. The secondary endpoints are Physicians and Patients self assessment score.
| Condition | Intervention | Phase |
|---|---|---|
|
Androgenetic Alopecia |
Biological: Autologous Human Platelet Lysate (HPL) Other: 2 % Minoxidil and /or Finasteride |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) |
Resource links provided by NLM:
Further study details as provided by Kasiak Research Pvt. Ltd.:
Primary Outcome Measures:
- Change in Calibre & Density of Hair as assessed by Folliscope [ Time Frame: Day 0, Month 4, End of study - Month 6 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Photographic Assessment [ Time Frame: Day 0, Month1, Month 2, Month 3, Month 4, Month 5, Month 6 ] [ Designated as safety issue: No ]
Other Outcome Measures:
- Physician's Assessment Score [ Time Frame: End of study - Month 6 ] [ Designated as safety issue: No ]
- Patient's Assessment Score [ Time Frame: End of study - Month 6 ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | November 2012 |
| Estimated Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Study arm A
Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
|
Biological: Autologous Human Platelet Lysate (HPL)
Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
Other Name: Autologous Human Platelet Lysate (HPL)
|
|
Control Arm B
Control arm B will include subjects receiving Standard therapy
|
Other: 2 % Minoxidil and /or Finasteride
Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
Other Name: 2 % Minoxidil and /or Finasteride
|
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male subjects, aged between 18 to 50 years (both inclusive) and in general good health
- Subjects willing to refrain from other AGA treatments during the entire study duration
- Subjects who are willing to give informed consent and adhere to the study protocol.
Exclusion Criteria:
- Subjects aged <18 or > 50 years
- Subjects with dermatological disorder of scalp that might interfere with study evaluation
- Subjects on Anti-coagulant therapy
- Subjects with clinically significant medical or psychiatric disease as determined by the investigator.
- Subjects with dermatological disorder of scalp that might interfere with study evaluation
- Subjects unwilling to or unable to comply with the study protocol.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01643629
Locations
| India | |
| Kasiak Research Pvt Ltd | |
| Thane, Maharashtra, India, 400610 | |
Sponsors and Collaborators
Kasiak Research Pvt. Ltd.
Investigators
| Principal Investigator: | Rajendarsingh Rajput, Dr. | Dr. Rajesh Rajput Hair Restore |
| Principal Investigator: | Sandeep Sattur, Dr. | Hairrevive |
More Information
No publications provided
| Responsible Party: | Kasiak Research Pvt. Ltd. |
| ClinicalTrials.gov Identifier: | NCT01643629 History of Changes |
| Other Study ID Numbers: | KRPL/HPL-AGA/11-12/001A |
| Study First Received: | July 12, 2012 |
| Last Updated: | July 24, 2012 |
| Health Authority: | India: Institutional Review Board |
Additional relevant MeSH terms:
|
Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Minoxidil Finasteride |
Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Vasodilator Agents 5-alpha Reductase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013